Telomir Pharmaceuticals, Inc. Common StockTELONASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
41.99%
↓ 76% below average
Average (3y)
172.41%
Historical baseline
Range
High:558.70%
Low:0.00%
Volatility
324.1%
High variability
| Period | Value |
|---|---|
| 2024 | 41.99% |
| 2023 | 88.95% |
| 2022 | 558.70% |
| 2021 | 0.00% |